K. Petersen

Optimization of allosteric MEK inhibitors. Part 1: Venturing into underexplored SAR territories.

S. Hammer, G. Siemeister, R. Hillig, 2013, Bioorganic & medicinal chemistry letters.

Oncogenes meet metabolism. From deregulated genes to a broader understanding of tumour physiology. Preface.

G. Kroemer, T. Steger-Hartmann, H. Keun, 2007, Ernst Schering Foundation symposium proceedings.

Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS–SOS1 interaction

H. Briem, G. Siemeister, D. Moosmayer, 2019, Proceedings of the National Academy of Sciences.

BAY 1143269, a novel MNK1 inhibitor, targets oncogenic protein expression and shows potent anti-tumor activity.

P. Lienau, D. Mumberg, C. Lange, 2017, Cancer letters.

Bay846, a new irreversible small molecule inhibitor of EGFR and Her2, is highly effective against malignant brain tumor models

O. Politz, D. Post, Sandra McGillis, 2012, Investigational New Drugs.

Functional and Structural Characterization of Bub3·BubR1 Interactions Required for Spindle Assembly Checkpoint Signaling in Human Cells*

F. Prinz, Dorothee Andres, A. Fernández-Montalván, 2016, The Journal of Biological Chemistry.

Discovery and Characterization of BAY-805, a Potent and Selective Inhibitor of Ubiquitin-Specific Protease USP21

P. Lienau, C. Arrowsmith, M. Vedadi, 2023, Journal of medicinal chemistry.